

### Instructions

form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts. electronically. It contains programming that allows appropriate data display. Each author should submit a separate influence how they receive and understand your work. The form is designed to be completed electronically and stored The purpose of this form is to provide readers of your manuscript with information about your other interests that could

### Identifying information.

## 2. The work under consideration for publication.

work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check

# Relevant financial activities outside the submitted work.

in general, not just in the area of EGFR or lung cancer. that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that

should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to

perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be

### Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties

## Relationships not covered above

potentially influencing, what you wrote in the submitted work Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of

### **Definitions**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes **Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency **Licensed:** The patent has been licensed to an entity, whether

Royalties: Finds are coming in to you or your institution due to you

Royalties: Funds are coming in to you or your institution due to your patent

Llovet

21/10/1019



Section 1.					
Given Name (First Name)     Josep M	2. Surnan Llovet	2. Surname (Last Name) Llovet	ie)		3. Date 15-April-2019
4. Are you the corresponding author?	Yes	No.			
5. Manuscript Title The oncogenic role of hepatitis delta virus in hepatocellular carcinoma	rus in hepa	tocellular c	arcinoma	ALL THE STATE OF T	
6. Manuscript Identifying Number (if you know it) JHEPR-D-19-00020	now it)	Alliand			
Section 2. The Work Under Consideration for Publication	onsiderat	ion for Pu	ıblication		
Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?	ive payment , but not lim	or services ited to gran	from a third party ( s, data monitoring	governme board, stu	Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?
Are there any relevant conflicts of interest?		]Yes 🗸 No	ō		
Section 3. Relevant financial activities outside the submitted work.	activities	outside t	he submitted v	work.	
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .	n the table bed in the bort relation	to indicate instruction nships that	whether you has s. Use one line fo were <b>present d</b> u	ve financ r each en <b>uring the</b>	ial relationships (regardless of amount tity; add as many lines as you need by 36 months prior to publication.
Are there any relevant conflicts of interest? $\boxed{\checkmark}$ Yes If yes, please fill out the appropriate information below	est? 🗸 Yes ormation belov	es No elow.	ło		
Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Bayer Healthcare pharmaceuticals					
Eisai Inc					
Bristol Myers Squibb					
psen					
Boehringer-Ingelheim					
Eli Lilly					
Celsion Corporation					
Exelixis		<			

Llovet

810131/19



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Merck		☑			
Glycotest		≺			
Navigant		≤			
Leerink Swann LLC		≺			
Midatech		☑			
Fortress Biotech, Inc		☑			
Spring Bank Pharmaceuticals		◁			
Nucleix		☑			
Can-Fite Biopharma		<			

D	10
o you have any paten	section 4.
/ patents, whether p	Intellectual
lanned, ı	Property P
oending or issued, broadly relevant to the work	atents & Cop
sued, broadly re	pyrights
levant to the v	
vork?	
Yes	
✓ No	Virt

### Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

 $\checkmark$  No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

1100/21/h

Llovet



Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box

Nucleix, personal fees from Can-Fite Biopharma, outside the submitted work; Midatech, personal fees from Fortress Biotech, Inc, personal fees from Spring Bank Pharmaceuticals, personal fees from personal fees from Glycotest, personal fees from Navigant, personal fees from Leerink Swann LLC, personal fees from personal fees from Eli Lilly, personal fees from Celsion Corporation, personal fees from Exelixis, personal fees from Merck, grants and personal fees from Bristol Myers Squibb, grants and personal fees from Ipsen, grants from Boehringer-Ingelheim, Dr. Llovet reports grants and personal fees from Bayer Healthcare pharmaceuticals, grants and personal fees from Eisai Inc.

### **Evaluation and Feedback**

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Llovet

2101/21/4



### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### Identifying information.

### The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check

### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### **Intellectual Property.**

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

### Relationships not covered above. 5.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Moctezuma-Velazquez 1



Section 1. Identifying Inform	nation	
Given Name (First Name)  Carlos	2. Surname (Last Name) Moctezuma-Velazquez	3. Date 13-April-2019
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name  Josep M. Llovet and Augusto Villanueva
5. Manuscript Title The oncogenic role of hepatitis delta vi	rus in hepatocellular carcir	noma
6. Manuscript Identifying Number (if you ki JHEPR-D-19-00020	now it)	_
Section 2. The World Under Co	to the design of the little	
Did you or your institution at any time rece	g but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,
Section 3. Relevant financial	activities outside the s	submitted work.
of compensation) with entities as descr	ribed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by se present during the 36 months prior to publication.
Section 4. Intellectual Prope	rty Patents & Copyrig	yhts
Do you have any patents, whether plan	ned, pending or issued, bro	oadly relevant to the work? Yes V No

Moctezuma-Velazquez 2



Section 5. Polationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Moctezuma-Velazquez has nothing to disclose.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Moctezuma-Velazquez 3



### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### 1. Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

### 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

patent



Section 1.	Identifying Inforr	mation				
1. Given Name (Fi Augusto	irst Name)	2. Surname (La Villanueva	ast Name)		3. Date 15-April-2019	
4. Are you the co	responding author?	✓ Yes	No			
5. Manuscript Titl The Oncogenic	e Role of Hepatitis Delta	Virus in Hepatoo	cellular Carcinoma			
6. Manuscript Ide	ntifying Number (if you k 120	now it)				
Section 2.	The Work Under C	Consideration	for Publication			
any aspect of the statistical analysis	submitted work (includin	g but not limited			commercial, private foundatio design, manuscript preparatio	
Section 3.	Relevant financial	activities out	side the submitted	l work.		
of compensation clicking the "Add Are there any re	n) with entities as desc	ribed in the instreport relationshing rest? Yes	ructions. Use one line posthat were <b>present</b> No	for each entity	relationships (regardless of r; add as many lines as you r r <b>months prior to publicat</b>	need by
Name of Entity		Grant	sonal Non-Financial systems? Support?	Other?	omments	
Health Advances LLC			<b>✓</b>			
GroupH						
Gerson Lehrman Gro	pup		<b>✓</b>			
Champions Oncolog	у		<b>✓</b>			
Exelixis			<b>✓</b>			
Exact Sciences			<b>✓</b>			
Fujifilm Dako Diagno	ostics		<b>✓</b>			
NGM Pharmaceutica	ls		<b>√</b>			



Name of Entity	Gı	rant•	_	on-Financial Support?	Other?	Comments
Nucleix			<b>✓</b>			
Section 4. Intellectual	Property -	- Patents	s & Copyri	ghts		
Do you have any patents, wheth If yes, please fill out the appropi Excess rows can be removed by	riate informa	ntion belo	w. If you ha	•		work? Yes No ty press the "ADD" button to add a row.
Patent?	Pending?	Issued?	Licensed?	Royalties?	License	e? Comments
Compositions, kits, and methods for identification, assessment, prevention, and therapy of hepatic disorders (US13124487)		<b>✓</b>				
Method for the prognosis of hepatocellular carcinoma (EP20140382535)		<b>✓</b>				
Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features	<b>✓</b>					
Section 5. Relationshi	ps not cov	ered abo	ove			
Are there other relationships or potentially influencing, what yo			-	eive to have	influenced	d, or that give the appearance of
Yes, the following relationsh  No other relationships/cond	•					
At the time of manuscript accep						sary, update their disclosure statements. elationships.



### Section 6.

### **Disclosure Statement**

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Villanueva reports personal fees from Health Advances LLC, personal fees from GroupH, personal fees from Gerson Lehrman Group, non-financial support from Champions Oncology, personal fees from Exelixis, personal fees from Exact Sciences, personal fees from Fujifilm Dako Diagnostics, personal fees from NGM Pharmaceuticals, personal fees from Nucleix, outside the submitted work; In addition, Dr. Villanueva has a patent Compositions, kits, and methods for identification, assessment, prevention, and therapy of hepatic disorders (US13124487) issued, a patent Method for the prognosis of hepatocellular carcinoma (EP20140382535) issued, and a patent Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features pending.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

### Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Puigvehi 1



Section 1. Identifying Inform	ation	
Given Name (First Name)  Marc	2. Surname (Last Name) Puigvehi	3. Date 13-April-2019
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author's Name
5. Manuscript Title The oncogenic role of hepatitis delta vii	rus in hepatocellular carcir	noma
6. Manuscript Identifying Number (if you kn JHEPR-D-19-00020	now it)	_
Continue 2		
Section 2. The Work Under Co	onsideration for Public	ation
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,
Section 3. Relevant financial	activities outside the s	ubmitted work.
of compensation) with entities as descri	bed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by se <b>present during the 36 months prior to publication</b> .
Section 4. Intellectual Proper	ty Patents & Copyrig	jhts
Do you have any patents, whether plant		

Puigvehi 2



Section 5.	
Section 5.	Relationships not covered above
	relationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	ationships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements Irnals may ask authors to disclose further information about reported relationships.
- · · -	
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Puigvehi has	nothing to disclose.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Puigvehi 3